Canaccord Genuity Gives Buy Rating to OraSure Technologies (OSUR)
Shares of OraSure Technologies traded down 3.56% during mid-day trading on Wednesday, hitting $10.56. OraSure Technologies has a 52 week low of $6.29 and a 52 week high of $12.28. The company’s market cap is $508.8 million.
OraSure Technologies last released its earnings data on Wednesday, May 2nd. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. Analysts expect that OraSure Technologies will post $-0.05 EPS next quarter.
A number of other analysts have also recently weighed in on OSUR. Analysts at RBC Capital (NYSE: RY) initiated coverage on shares of OraSure Technologies in a research note to investors on Tuesday, April 10th. They set an “outperform” rating on the stock. Separately, analysts at JMP Securities initiated coverage on shares of OraSure Technologies in a research note to investors on Tuesday, March 27th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, analysts at McNicoll Lewis & Vlak upgraded shares of OraSure Technologies to a “buy” rating in a research note to investors on Wednesday, March 21st.
OraSure Technologies, Inc. is engaged in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its oral fluid technologies, as well as other diagnostic products, including immunoassays and other in-vitro diagnostic tests that are used on other specimen types, and other medical devices used for the removal of benign skin lesions by cryosurgery or freezing.